8-K
QHSLab, Inc. (USAQ)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): May 2, 2024
QHSLab,Inc.
(Exact Name of Registrant as Specified in its Charter)
0-19041
(Commission File No.)
| Nevada | 30-1104301 |
|---|---|
| (State<br><br> <br>of<br> Incorporation) | (I.R.S.<br> Employer<br><br> <br>Identification<br> No.) |
| 901<br> Northpoint Parkway Suite 302 West Palm Beach<br><br> <br>FL<br> 33407 | 33407 |
| --- | --- |
| (Address<br> of Principal Executive Offices) | (ZIP<br> Code) |
Registrant’s telephone number, including area code: (929) 379-6503
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c) |
Securitiesregistered pursuant to Section 12(g) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.0001 par value | USAQ | N/A |
Item7.01 Regulation FD Disclosure.
On May 2, 2024, QHSLab, Inc. (the “Company”) issued a press release announcing the appointment of Dr. Marcos Sanchez-Gonzalez as the new Vice President of Medical and Scientific Affairs. This announcement is part of the Company’s ongoing efforts to enhance its leadership team and expand its expertise in medical and scientific areas.
The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.
We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.
We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (https://twitter.com/qhslabinc), LinkedIn account (https://www.linkedin.com/company/65407282/), Facebook account (https://www.facebook.com/QHSLabs) and Instagram account (https://www.instagram.com/qhslabs/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.
Item9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits.
The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.
| Exhibit<br><br> <br>No. | Description |
|---|---|
| 99.1 | Press Release dated May 2, 2024 – QHSLab, Inc. Enhances Leadership Team with Dr. Marcos Sanchez-Gonzalez as New VP of Medical and Scientific Affairs |
| 104 | Cover<br> Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date:<br> May 2, 2024 | |
|---|---|
| QHSLab,<br> Inc. | |
| /s/ Troy Grogan | |
| Name: | Troy<br> Grogan |
| Title: | CEO<br> and Chairman |
Exhibit99.1
QHSLab,Inc. Enhances Leadership Team with Dr. Marcos Sanchez-Gonzalez as New VP of Medical and Scientific Affairs
WESTPALM BEACH, FL, May 2, 2024 (GLOBE NEWSWIRE) — QHSLab, Inc. (the “Company”) (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based healthcare solutions, today announced the appointment of Dr. Marcos Sanchez-Gonzalez as the new Vice President of Medical and Scientific Affairs.
StrategicRole and Objectives:
In his new role, Dr. Sanchez-Gonzalez will spearhead the development, management, and execution of comprehensive education, communication and business development strategies aimed at clinicians and providers. His responsibilities include enhancing provider relationships and supporting the clinical applications of our cutting-edge technologies, products, and services. Dr. Sanchez-Gonzalez will also lead the creation and implementation of key educational events, directly and through our growing medical practice networks.
PrincipalDuties and Responsibilities:
● Educational Support and Training: Dr. Sanchez-Gonzalez will support our sales efforts, providing scientific expertise to customers and potential customers. He will play a critical role in educating clinicians, staff, and partners about our technologies.
● Training and Relationship Management: He will manage and execute training for in-house personnel, field staff, and alliance partners on key technologies and clinical applications, while also managing vital clinician-provider relationships.
● Collaboration and Development: Dr. Sanchez-Gonzalez will work closely with our Marketing, Operations and Software Development teams to identify opportunities that promote the utilization of our products and support our corporate strategies.
● Post-market Clinical Evaluation: He will establish and manage a post-market clinical evaluation portfolio, which includes, data analysis, literature and case studies aligned with our corporate needs.
● Conference Participation: Dr. Sanchez-Gonzalez will attend and present at industry conferences and meetings, serving as a technical and medical expert on key technologies.
Roleas a Medical Science Liaison:
Dr. Sanchez-Gonzalez will leverage his credentials to forge partnerships with target medical organizations, enhancing service delivery and integrating clinical insights into QHSLab’s operational framework. His focus on making our services clinically relevant and efficiently delivered will support QHSLab’s mission to improve patient outcomes and enhance the quality of healthcare.
ExecutiveCommentary:
Troy Grogan, President and CEO of QHSLab, Inc., expressed his enthusiasm about the new appointment, stating, “We are delighted to expand Dr. Marcos Sanchez-Gonzalez’s role at QHSLab to a full time basis. His extensive knowledge and innovative approach to medical and scientific affairs are exactly what QHSLab needs as we enter our next phase of growth. I have worked with Dr Sanchez-Gonzalez’s in various capacities for over five years and am confident that Marcos will make significant contributions to our company, enhancing our capabilities and ensuring our technologies meet the highest standards of efficacy and efficiency.”
For more information about QHSLab and our healthcare solutions, please visit www.qhslab.com.
AboutQHSLab, Inc.
QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving their revenues.
Forward-LookingStatements
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
InvestorRelations Contact:
OliviaGiamanco
QHSLab,Inc.
(929)379-6503
ir@usaqcorp.com
https://twitter.com/QHSLabInc